Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR | Benzinga

Q: What sector and industry does Atea Pharmaceuticals (AVIR) operate in?

Atea Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Explore Atea Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AVIR.

Open	$3.12
Close	$3.22
Volume / Avg.	557.68K / 366.01K
Day Range	$3.08 - $3.29
52 Wk Range	2.75 - 4.14
Market Cap	$273.68M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	59
Short Interest	4.68%
Days to Cover	9.96

Recent News

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.

Vandana Singh

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.

Vandana Singh

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Open	$3.12
Close	$3.22
Volume / Avg.	557.68K / 366.01K
Day Range	$3.08 - $3.29
52 Wk Range	2.75 - 4.14
Market Cap	$273.68M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	59
Short Interest	4.68%
Days to Cover	9.96

About Atea Pharmaceuticals Inc

Sector

Health Care

Industry

Pharmaceuticals

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, devel...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Atea Pharmaceuticals (AVIR) stock?

You can purchase shares of Atea Pharmaceuticals (NASDAQ:AVIR) through any online brokerage.

View our list of the best stock brokerages

Who are Atea Pharmaceuticals (AVIR) competitors?

Other companies in Atea Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), Zevra Therapeutics (NASDAQ:ZVRA), Third Harmonic Bio (NASDAQ:THRD), SNDL (NASDAQ:SNDL) and Bioage Labs (NASDAQ:BIOA).

What is the forecast, or price target, for Atea Pharmaceuticals (AVIR) stock?

Atea Pharmaceuticals has a consensus price target of $6.44.

What is the current price for Atea Pharmaceuticals (AVIR)?

The stock price for Atea Pharmaceuticals (NASDAQ: AVIR) is $3.2 last updated March 21, 2025 at 4:16 PM EDT.

Does Atea Pharmaceuticals (AVIR) pay a dividend?

There are no upcoming dividends for Atea Pharmaceuticals.

When is Atea Pharmaceuticals (NASDAQ:AVIR) reporting earnings?

Atea Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 13, 2025.

Is Atea Pharmaceuticals (AVIR) going to split?

There is no upcoming split for Atea Pharmaceuticals.

What sector and industry does Atea Pharmaceuticals (AVIR) operate in?

Atea Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Atea Pharmaceuticals Stock Price, Quotes and Forecasts

Atea Pharmaceuticals (AVIR) Forecast